Cancer treatment is entering a new era, and combination therapies are leading the way. Increasingly, the biggest breakthroughs come not from adding a novel treatment to chemotherapy, but from branded-branded combinations that bring together multiple innovative medicines. While these advances create new possibilities for patients, they also challenge conventional approaches to value assessment, pricing, and reimbursement. Many HTA and reimbursement frameworks were designed to evaluate single interventions and are not equipped for this growing complexity. As a result, key questions are emerging around how value should be assessed, how innovation should be rewarded, and how patients can gain timely access. This educational symposium will bring together leading experts from Europe and the Asia-Pacific region to explore whether today's frameworks can keep pace with tomorrow's oncology innovations. Drawing on lessons from Europe and ongoing policy discussions across Asia-Pacific, the session combines expert perspectives, practical examples, and forward-looking discussion. Whether you work in HTA, market access, policy, or reimbursement, it offers a timely opportunity to engage with one of the most consequential debates in cancer care. Speakers will be confirmed closer to the event.
Sponsored by Charles River Associates
Code
20
Topic
Health Policy & Regulatory, Health Technology Assessment